Home/Investors/Public market investors

Public market investors

Biotech Investor · 11 portfolio companies

Portfolio

11

Combined Value

$40.1B

Focus Areas

19

Top Stage

Phase 2

Investment Focus

Oncology Immunology Autoimmune Hematology/Oncology Cardiovascular Orthopedic Neuroscience Inflammation Inflammatory Diseases Critical Care Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Rare Diseases Ophthalmology Neurology

Portfolio Companies

Company	Stage	Valuation	Focus
REVOLUTION Medicines	Phase 2	$30.4B	Oncology
Kymera Therapeutics	Phase 1b	$7.0B	Immunology, Oncology
Mesoblast	Approved	$1.9B	Hematology/Oncology, Cardiovascular
Contineum Therapeutics	Phase 2	$545.8M	Neuroscience, Immunology
InflaRx	Phase 3	$187.2M	Inflammatory Diseases, Critical Care
NextCure	Phase 2	$36.2M	Oncology, Immunology
NeuroSense Therapeutics	Phase IIb	$30.0M	Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis
Akari Therapeutics	Phase 3	$7.5M	Rare Diseases, Inflammation
Unity Biotechnology	Phase 2	$3.4M	Ophthalmology, Neurology
Magenta Therapeutics	Phase 2	—	Oncology, Hematology
Innolake Biopharm	phase-3	—	Oncology, Immunology

Frequent Co-Investors

Legend Capital1 shared The Column Group1 shared Boyu Capital1 shared Vertex Ventures HC1 shared Third Rock Ventures1 shared Sanofi1 shared NovaQuest Capital Management1 shared Pivotal Bioventure Partners1 shared